The FDA approval of Zeiss’ MEL 90 gives surgeons improved optionality in refractive surgical procedures. Image credit: Zeiss / PRnewswire.

The US Food and Drug Administration (FDA) has approved Zeiss Medical Technology’s MEL 90 excimer laser technology.

MEL 90 is integrated with the German company’s Corneal Refractive Workflow ecosystem, which encompasses the VISUMAX 800 femtosecond laser with SMILE PRO for refractive surgeries. These applications include laser-assisted in situ keratomileusis (LASIK), in which a patient’s cornea is reshaped to improve their vision, and surgical procedures such as keratoplasty and incisions.

Used for sphero-cylindrical (SCA) corrections, MEL 90 has been approved for the treatment of myopia, hyperopia, and mixed astigmatism, a condition whereby hyperopic and myopic correction is required.

Magnus Reibenspiess, head of strategic business unit ophthalmology at Zeiss Medical Technology, said: “The increasing global adoption of laser vision correction reflects the advancements and positive impact the technology continues to have on the quality of life for patients.

“With the integration of the Zeiss MEL 90, surgeons can confidently care for their patients with greater workflow efficiency and performance with enhanced outcomes.”

According to Zeiss, MEL 90’s Triple-A (Advanced Ablation Algorithm) technology  offers a “high degree of accuracy, reproducibility and predictability” during procedures and gives surgeons the ability to perform applications such as tissue-saving ablation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Zeiss continues to break new ground as a leader in the laser vision correction market, reflecting our ongoing commitment to and support of US surgeons and patients with the latest refractive innovation that helps set practices apart and provides more options to more patients,” said Andrew Chang, head of global sales for Zeiss Medical Technology.

“With the availability of the Zeiss MEL 90 in the US market, surgeons can now offer an integrated workflow of refractive technology to help reach new patients and provide excellent outcomes for them.”

According to GlobalData analysis, the global ophthalmic devices market was worth around $7.92bn in 2024 and is forecast to reach a valuation of around $9.92bn by 2033.

In October 2023, Zeiss entered a long-term partnership with Boehringer Ingelheim to develop predictive analytics to help facilitate the early detection of eye diseases and offer more personalised treatments to avoid vision loss for serious eye disease patients.